China’s National Medical Products Administration (NMPA) has granted approval to the new drug application (NDA) of Shanghai Fosun Pharmaceutical Industrial Development’s phosphate absorption inhibitor, Tenapanor Hydrochloride tablets, intended for controlling levels of serum phosphorus in dialysis patients with chronic kidney disease (CKD).
Health Canada has granted marketing authorisation to Kashiv BioSciences’ long-acting G-CSF biosimilar, Pegfilgrastim injection.
Biocon Biologics, a subsidiary of Biocon, has launched Yesintek (ustekinumab-kfce), a biosimilar to Stelara, in the US.
Tiziana Life Sciences has entered into a product development services agreement with US contract development and manufacturing organisation (CDMO) Renaissance Lakewood aimed at improving the present formulation and enhancing the production of intranasal foralumab.
The Japan’s Ministry of Health, Labour and Welfare has granted approval to Genmab's Epkinly (epcoritamab) for treating individuals with relapsed or refractory (R/R) follicular lymphoma who have undergone at least two prior therapies.
Biotechnology company Nona Biosciences has entered into a licensing agreement with the University of Alabama at Birmingham (UAB) to advance its B cell development research.
Perceive Pharma has secured $15m in a Series A funding round to expedite neuroprotective therapeutic development in glaucoma and other indications.
SpringWorks Therapeutics has selected Onco360 as national specialty pharmacy partner for Gomekli (mirdametinib).
Conduit Pharmaceuticals has announced a partnership with Charles River Laboratories to assess AZD1656 as well as its derivatives in a Systemic Lupus Erythematosus (SLE) model.
UK-based biotechnology company ExpressionEdits has announced a partnership and licensing agreement with Boehringer Ingelheim for optimising the expression of gene therapies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.